Experimental drug aims to destroy Amyloid-Causing cells in newly diagnosed patients
NCT ID NCT07524634
First seen Apr 23, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tests an experimental drug called elranatamab in people newly diagnosed with light chain (AL) amyloidosis who have not yet had treatment. The drug works by helping the body's immune cells find and destroy the abnormal plasma cells that cause the disease. Researchers want to see if it can produce deep remissions and improve organ function, and they will compare two different dosing schedules. About 64 participants will receive the drug as injections under the skin over 6 months, with follow-up for up to 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOID LIGHT-CHAIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.